Risdiplam
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Risdiplam: From Spinal Muscular Atrophy to Acne (Disease)
One-Sentence Summary
Risdiplam is an SMN2 mRNA splicing modulator originally developed for spinal muscular atrophy (SMA). The TxGNN model predicts it may be effective for Acne (Disease), but this prediction is currently supported by 0 clinical trials and 0 publications, with no known mechanistic rationale.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Spinal Muscular Atrophy (SMA) |
| Predicted New Indication | Acne (Disease) |
| TxGNN Prediction Score | 99.45% |
| Evidence Level | L5 |
| Norway Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for risdiplam is not available (data gap). Based on known information, risdiplam is an SMN2 mRNA splicing modulator used in spinal muscular atrophy, acting to increase functional SMN protein expression in motor neurons. Its efficacy in SMA is well established.
However, this mechanism has no known or plausible molecular connection to acne, which involves follicular/sebaceous gland inflammation, androgen metabolism, and abnormal keratinization. The TxGNN score reflects only knowledge-graph embedding similarity rather than a validated biological pathway, and the absence of any supporting clinical trials or literature further weakens confidence in this prediction.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Norway Market Information
Risdiplam is not currently marketed in Norway; no authorization records are available.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is based solely on TxGNN model output (L5) with no clinical trial or literature support, and the proposed mechanistic link between an SMN2 splicing modulator and acne pathophysiology is not biologically plausible.
To proceed, the following is needed:
- TFDA/regulatory label data (warnings, contraindications) — currently blocking (DG001)
- Confirmed mechanism of action (MOA) data from DrugBank or primary literature (DG002)
- Independent mechanistic or preclinical evidence linking SMN2 modulation to dermatological/acne pathways before further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.